Western blot analysis of SGK1 expressed in Mouse brain,HeLa,293T using SGK1 Rabbit mAb at 1:1000. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:5000. Lysates/proteins: 30ug per lane. Blocking buffer: 5% non-fat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 120s.
Immunohistochemical analysis of paraffin-embedded human lung cancer, using SGK1 Antibody.
Western blot analysis of SGK1 expressed in Mouse brain,HeLa,293T using SGK1 Rabbit mAb at 1:1000. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:5000. Lysates/proteins: 30ug per lane. Blocking buffer: 5% non-fat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 120s.
Immunohistochemistry - SGK1 Rabbit mAb
Immunohistochemical analysis of paraffin-embedded human lung cancer, using SGK1 Antibody.
This gene encodes a serine/threonine protein kinase that plays an important role in cellular stress response. This kinase activates certain potassium, sodium, and chloride channels, suggesting an involvement in the regulation of processes such as cell survival, neuronal excitability, and renal sodium excretion. High levels of expression of this gene may contribute to conditions such as hypertension and diabetic nephropathy. Several alternatively spliced transcript variants encoding different isoforms have been noted for this gene.
Expressed in most tissues with highest levels in the pancreas, followed by placenta, kidney and lung. Isoform 2 is strongly expressed in brain and pancreas, weaker in heart, placenta, lung, liver and skeletal muscle.
功能
Serine/threonine-protein kinase which is involved in the regulation of a wide variety of ion channels, membrane transporters, cellular enzymes, transcription factors, neuronal excitability, cell growth, proliferation, survival, migration and apoptosis. Plays an important role in cellular stress response. Contributes to regulation of renal Na+ retention, renal K+ elimination, salt appetite, gastric acid secretion, intestinal Na+/H+ exchange and nutrient transport, insulin-dependent salt sensitivity of blood pressure, salt sensitivity of peripheral glucose uptake, cardiac repolarization and memory consolidation. Up-regulates Na+ channels: SCNN1A/ENAC, SCN5A and ASIC1/ACCN2, K+ channels: KCNJ1/ROMK1, KCNA1-5, KCNQ1-5 and KCNE1, epithelial Ca2+ channels: TRPV5 and TRPV6, chloride channels: BSND, CLCN2 and CFTR, glutamate transporters: SLC1A3/EAAT1, SLC1A2 /EAAT2, SLC1A1/EAAT3, SLC1A6/EAAT4 and SLC1A7/EAAT5, amino acid transporters: SLC1A5/ASCT2, SLC38A1/SN1 and SLC6A19, creatine transporter: SLC6A8, Na+/dicarboxylate cotransporter: SLC13A2/NADC1, Na+-dependent phosphate cotransporter: SLC34A2/NAPI-2B, glutamate receptor: GRIK2/GLUR6. Up-regulates carriers: SLC9A3/NHE3, SLC12A1/NKCC2, SLC12A3/NCC, SLC5A3/SMIT, SLC2A1/GLUT1, SLC5A1/SGLT1 and SLC15A2/PEPT2. Regulates enzymes: GSK3A/B, PMM2 and Na+/K+ ATPase, and transcription factors: CTNNB1 and nuclear factor NF-kappa-B. Stimulates sodium transport into epithelial cells by enhancing the stability and expression of SCNN1A/ENAC. This is achieved by phosphorylating the NEDD4L ubiquitin E3 ligase, promoting its interaction with 14-3-3 proteins, thereby preventing it from binding to SCNN1A/ENAC and targeting it for degradation. Regulates store-operated Ca(+2) entry (SOCE) by stimulating ORAI1 and STIM1. Regulates KCNJ1/ROMK1 directly via its phosphorylation or indirectly via increased interaction with SLC9A3R2/NHERF2. Phosphorylates MDM2 and activates MDM2-dependent ubiquitination of p53/TP53. Phosphorylates MAPT/TAU and mediates microtubule depolymerization and neurite formation in hippocampal neurons. Phosphorylates SLC2A4/GLUT4 and up-regulates its activity. Phosphorylates APBB1/FE65 and promotes its localization to the nucleus. Phosphorylates MAPK1/ERK2 and activates it by enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2. Phosphorylates FBXW7 and plays an inhibitory role in the NOTCH1 signaling. Phosphorylates FOXO1 resulting in its relocalization from the nucleus to the cytoplasm. Phosphorylates FOXO3, promoting its exit from the nucleus and interference with FOXO3-dependent transcription. Phosphorylates BRAF and MAP3K3/MEKK3 and inhibits their activity. Phosphorylates SLC9A3/NHE3 in response to dexamethasone, resulting in its activation and increased localization at the cell membrane. Phosphorylates CREB1. Necessary for vascular remodeling during angiogenesis. Sustained high levels and activity may contribute to conditions such as hypertension and diabetic nephropathy. Isoform 2 exhibited a greater effect on cell plasma membrane expression of SCNN1A/ENAC and Na+ transport than isoform 1.
a. 贴壁培养细胞收集
去除贴壁细胞的培养液,用PBS、NS或无血清培养基清洗1次,低速离心,弃上清,留取沉淀。
b. 悬浮培养细胞收集
速离心悬浮细胞,弃上清,收集沉淀。手指轻弹细胞,使其松散。
c. 组织样本收集
把组织剪切成细小的碎片,越小越好。取液氮或超低温冰箱中冷冻30min以上的组织,迅速用液氮研磨,研磨过程尽量控制在1~2min之内,以减少蛋白的降解。
(2)总蛋白提取
a. 细胞/组织裂解
将装有细胞沉淀或组织碎片的容器完全插入冰中。细胞沉淀按照1mL裂解液/107个细胞(1个T75培养瓶细胞量)的比例加入相应体积的裂解液(细胞量足够时都加入3mL,不足时根据细胞量计算),裂解20min,每隔5min将离心管置于涡旋振荡仪上震荡10s。组织碎片按照0.5mL 裂解液/100mg组织向匀浆器中加入蛋白裂解液,每3min研磨一次,重复5次,使组织尽量碾碎。(裂解液中根据需要选择添加或不添加蛋白酶抑制剂)。
b. 离心
把裂解好的样品配平后,置于预冷的高速冷冻离心机中,12000 rpm,15min。
c. 蛋白变性
完成离心后,上清即为蛋白提取液。吸取少量蛋白提取液做蛋白浓度测定。向剩余的蛋白提取液的离心管中加入1/5上清体积的5×Loading Buffer(最终工作液为1X),待干式恒温器温度升至95℃后,将1.5mL离心管插入加热孔中,95℃加热变性10min,待液体完全冷却后置于-20℃保存。
(3)蛋白浓度测定(BCA法)
a. BCA工作液的配置
根据样品数量,按50体积BCA试剂A加入1体积BCA试剂B(50:1)配置适量BCA工作液,充分混匀。BCA工作液室温24h内稳定。
b. 标准品测定
取10μl蛋白标准品(5mg/ml BSA)稀释至50μl,使终浓度为1mg/ml。稀释后的蛋白标准品可以-20℃长期保存。此标准品溶液的稀释液可使用去离子水或1*PBS。将标准品按0、1、2、4、8、12、16、20μl加入到96孔板中,加稀释液补足到20μl(见附表)。加适当体积样品到96孔板的样品孔中,如果样本不足20μl,需加稀释液补足到20μl。请注意记录样品体积。各孔加入200μl BCA工作液,37℃放置20-30min。用酶标仪测定A562,或540-595nm之间的其他波长吸光度。根据标准曲线和使用的样品体积计算出样品的蛋白浓度。
a. Western Transfer Buffer至少提前2h (即开始电泳后)放入-20℃冰箱预冷,但注意避免结冰。
b. 根据胶体大小,将Filter Paper及Nitrocellulose membrane剪裁至合适尺寸。
c. 目的蛋白>20KD选择0.45μm NC膜/PVDF膜;目的蛋白<20KD选择0.2μmNC膜或PVDF膜,选择完毕后将NC膜放在Western Transfer Buffer中浸泡备用,注意如使用的是PVDF膜需先放入甲醇中浸泡5-10min,再放入Western Transfer Buffer中浸泡备用。
(2)裂解液&洗杂液:Cell lysis buffer for IP (without inhibitors)
(3)蛋白酶抑制剂
(4)封闭液:含 3% BSA 的 1X PBS
(5)1×PBS 缓冲液
(6)5×loding buffer(使用时用去离子水稀释至工作浓度即可)
(7)Control IgG (AC005/ AC011/AC034)
二、实验步骤
1、样本处理
(1)贴壁培养细胞
a. 取裂解液室温溶解混匀,根据需要选择添加或不添加蛋白酶抑制剂。
b. 去除贴壁细胞的培养液,用PBS、NS或无血清培养基清洗1次,低速离心,弃上清,留取沉淀。
c. 按照6孔板每孔加入100~200μl裂解液的比例,加入裂解液。移液器轻轻吹打,使裂解液和细胞充分接触。通常裂解液作用于细胞1~5s内,细胞会被裂解。
d. 1000~12000g,离心3~5min(如果用冷冻离心机4℃效果更佳),取上清。
(2)悬浮培养细胞
a. 取裂解液室温溶解混匀,根据需要选择添加或不添加蛋白酶抑制剂。
b. 速离心悬浮细胞,弃上清,收集沉淀。
c. 手指轻弹细胞,使其松散。按照6孔板每孔加入100~200μl裂解液的比例,加入NP-40裂解液。通常6孔板每孔加入100~200μl裂解液已经足够,但如果细胞密度非常高可以适当加大裂解液的用量150~200μl,再用手指轻弹以充分裂解细胞。充分裂解后应无明显沉淀。
d. 1000~12000g,离心3~5min(如果用冷冻离心机4℃效果更佳),取上清。
(3)组织样本
a. 取裂解液室温溶解混匀,根据需要选择添加或不添加蛋白酶抑制剂。
b. 把组织剪切成细小的碎片,越小越好。
c. 取液氮或超低温冰箱中冷冻30min以上的组织,迅速用液氮研磨,研磨过程尽量控制在1~2min之内,以减少蛋白的降解。
d. 按照每20mg组织加入100~200μl裂解液的比例,加入含有PMSF的裂解液。冰上或4℃裂解30-60min。(步骤3、4也可采用以下过程:按照每20mg组织加入100~200μl裂解液的比例加入NP-40裂解液。用玻璃匀浆器或组织研磨器匀浆,直至充分裂解,过程尽量控制在1~2min之内,以减少蛋白的降解。)
e. 按照每20mg组织加入100~200μl裂解液的比例,加入裂解液。
f. 1000~12000g,4℃离心10~15min(如无低温离心机,室温下离心也可),取上清。
2、磁珠预处理
(1)将rProtein A/G Plus MaqPoly Beads颠倒或漩涡混匀,翻转瓶身发现底部无黑色沉淀即可。
(2)取30μl rProtein A/G Plus MaqPoly Beads至新的EP管中,放在磁分离器上,待溶液澄清后,用移液器吸弃保护液。
(3)将EP管从磁分离器上取下来,加入1ml Cell lysis buffer for IP (without inhibitors),混匀,放置在磁分离器上,收集磁珠,用移液器吸弃洗杂液,重复2次。